Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/26/2025

Management of Opioid-Induced Constipation in Patients on Suboxone

Introduction to Guideline Recommendations

  • The National Comprehensive Cancer Network (NCCN) guidelines recommend against the use of docusate for managing opioid-induced constipation, as it has not shown significant benefit 1

First-Line Therapy for Opioid-Induced Constipation

  • The NCCN guidelines suggest starting with a stimulant laxative, such as senna 8.6-17.2 mg daily, as prophylaxis when initiating Suboxone 2, 3
  • Bisacodyl 10-15 mg daily is also recommended as a first-line option, with the goal of achieving 1 non-forced bowel movement every 1-2 days 4, 5

Second-Line Options for Opioid-Induced Constipation

  • If stimulant laxatives are insufficient, adding an osmotic laxative such as polyethylene glycol (PEG) 17 g daily is recommended, as it is the most cost-effective option 2, 3
  • Lactulose 30-60 mL BID-QID and magnesium hydroxide 30-60 mL daily-BID are also recommended as second-line options 4, 5

Peripherally Acting Mu-Opioid Receptor Antagonists for Refractory Constipation

  • Methylnaltrexone 0.15 mg/kg subcutaneously every other day (maximum once daily) is recommended for refractory cases, as it works on gastrointestinal receptors without reducing opioid-mediated analgesia 4, 5, 6
  • Naldemedine is also recommended as an FDA-approved alternative 1

Critical Caveats and Considerations

  • Before escalating therapy, it is essential to rule out bowel obstruction, fecal impaction, hypercalcemia, hypokalemia, hypothyroidism, diabetes mellitus, and other constipating medications that can be discontinued 4, 5